Urology Hyperhidrosis Treatment of overactive bladder in women Botulinum Toxin type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine): that has not responded to at least three prior pharmacological prophylaxis therapies and whose condition is appropriately managed for medication overuse. Botulinum Toxin is not available for the treatment of facial ageing or excessive wrinkles For treatment of overactive bladder in women, bladder wall injection should only be used in the treatment of idiopathic detrusor over activity only in women who have not responded to conservative treatments (including antimuscarinic drugs e.g. oxybutynin) and who are willing and able to self catheterize. NICE notes that there is a gap in treatment between conservative treatment and surgery and Botulinum Toxin has been adopted to fill this position, however, this is in advance of high quality data on efficacy, safety and long term outcomes. An IPFR is required for all other circumstances. Neurosurgery WHSSC A10.8 Subthalamotomy Can only be undertaken in line with NICE guidance. Y11.4 for Parkinson’s (plus Disease An IPFR is required for all other circumstances. code G20.X)
Urology Hyperhidrosis Treatment of overactive bladder in women Botulinum Toxin type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine): that has not responded to at least three prior pharmacological prophylaxis therapies and whose condition is appropriately managed for medication overuse. Botulinum Toxin is not available for the treatment of facial ageing or excessive wrinkles For treatment of overactive bladder in women, bladder wall injection should only be used in the treatment of idiopathic detrusor over activity only in women who have not responded to conservative treatments (including antimuscarinic drugs e.g. oxybutynin) and who are willing and able to self catheterize. NICE notes that there is a gap in treatment between conservative treatment and surgery and Botulinum Toxin has been adopted to fill this position, however, this is in advance of high quality data on efficacy, safety and long term outcomes. An IPFR is required for all other circumstances. Neurosurgery WHSSC A10.8 Y11.4 (plus code G20.X) Subthalamotomy for Parkinson’s Disease Can only be undertaken in line with NICE guidance. An IPFR is required for all other circumstances.
Full%20INNU%20Policy%20Final%20Powys%20version%20Board%20approved.docx